Last reviewed · How we verify

Shaanxi Micot Pharmaceutical Technology Co., Ltd. — Portfolio Competitive Intelligence Brief

Shaanxi Micot Pharmaceutical Technology Co., Ltd. pipeline: 0 marketed, 0 filed, 1 Phase 3, 4 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 4 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
MT1013 MT1013 phase 3 PDE4 inhibitor PDE4 Immunology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Advenchen Pharmaceuticals, LLC. · 1 shared drug class
  2. Almirall, S.A. · 1 shared drug class
  3. Amgen · 1 shared drug class
  4. Arcutis Biotherapeutics, Inc. · 1 shared drug class
  5. Dr. Reddy's Laboratories Limited · 1 shared drug class
  6. Galderma R&D · 1 shared drug class
  7. GlaxoSmithKline · 1 shared drug class
  8. Handok Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Shaanxi Micot Pharmaceutical Technology Co., Ltd.:

Cite this brief

Drug Landscape (2026). Shaanxi Micot Pharmaceutical Technology Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/shaanxi-micot-pharmaceutical-technology-co-ltd. Accessed 2026-05-16.

Related